Biotech Values

[DewDiligence]

Additional granularity on 3Q16 Botox sales:

Worldwide sales of $690M were 72% US, 28% ex-US.

Of the US sales, 62% were for medical indications and 38% for cosmetic indications.

The breakdown of ex-US sales was the reverse: 40% for medical indications and 60% for cosmetic indications.

In all geographies, Botox's patient share in cosmetic indications is much greater than its dollar share in cosmetic indications because cosmetic indications use much less toxin per patient than medical indications.